NCT06680037View on ClinicalTrials.gov

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

January 1, 2029

Conditions
B-cell Mediated Autoimmune Disorders
Interventions
DRUG

Azercabtagene zapreleucel (azer-cel)

IV infusion

Trial Locations (5)

10025

RECRUITING

TG Therapeutics Investigational Trial Site, New York

40506

NOT_YET_RECRUITING

TG Therapeutics Investigational Trial Site, Lexington

44195

RECRUITING

TG Therapeutics Investigational Trial Site, Cleveland

68198

RECRUITING

TG Therapeutics Investigational Trial Site, Omaha

92093

RECRUITING

TG Therapeutics Investigational Trial Site, La Jolla

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT06680037 - A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | Biotech Hunter | Biotech Hunter